These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 20798377)

  • 1. The risk of deep venous thrombosis associated with injectable depot-medroxyprogesterone acetate contraceptives or a levonorgestrel intrauterine device.
    van Hylckama Vlieg A; Helmerhorst FM; Rosendaal FR
    Arterioscler Thromb Vasc Biol; 2010 Nov; 30(11):2297-300. PubMed ID: 20798377
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-acting contraceptive options.
    Kaunitz AM
    Int J Fertil Menopausal Stud; 1996; 41(2):69-76. PubMed ID: 8829701
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-acting contraceptives in adolescents.
    Tolaymat LL; Kaunitz AM
    Curr Opin Obstet Gynecol; 2007 Oct; 19(5):453-60. PubMed ID: 17885461
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of the levonorgestrel-releasing intrauterine system on the resistance to activated protein C (APC).
    van Vliet HA; Tchaikovski SN; Rosendaal FR; Rosing J; Helmerhorst FM
    Thromb Haemost; 2009 Apr; 101(4):691-5. PubMed ID: 19350113
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical experience with injectable progestogen- only contraceptives at University of Ilorin teaching hospital: a five year review.
    Balogun OR; Raji HO
    Niger Postgrad Med J; 2009 Dec; 16(4):260-3. PubMed ID: 20037621
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Depot medroxyprogesterone acetate, oral contraceptives and bone mineral density in a cohort of adolescent girls.
    Cromer BA; Stager M; Bonny A; Lazebnik R; Rome E; Ziegler J; Debanne SM
    J Adolesc Health; 2004 Dec; 35(6):434-41. PubMed ID: 15581522
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-acting progestogen contraceptives.
    Power J; Guillebaud J
    Practitioner; 2002 May; 246(1634):332, 335-9, 341. PubMed ID: 12043350
    [No Abstract]   [Full Text] [Related]  

  • 8. Contraceptive considerations in overweight teens.
    Kaneshiro B; Edelman A
    Curr Opin Obstet Gynecol; 2011 Oct; 23(5):344-9. PubMed ID: 21666461
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cerebral venous sinus thrombosis in users of four hormonal contraceptives: levonorgestrel-containing oral contraceptives, norgestimate-containing oral contraceptives, desogestrel-containing oral contraceptives and the contraceptive patch.
    Jick SS; Jick H
    Contraception; 2006 Oct; 74(4):290-2. PubMed ID: 16982227
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent developments in hormone delivery systems.
    Shulman LP; Nelson AL; Darney PD
    Am J Obstet Gynecol; 2004 Apr; 190(4 Suppl):S39-48. PubMed ID: 15105797
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advances in hormonal contraception.
    Gupta N
    Adolesc Med Clin; 2006 Oct; 17(3):653-71; abstract xi. PubMed ID: 17030284
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of metabolic and inflammatory outcomes in women who used oral contraceptives and the levonorgestrel-releasing intrauterine device in a general population.
    Morin-Papunen L; Martikainen H; McCarthy MI; Franks S; Sovio U; Hartikainen AL; Ruokonen A; Leinonen M; Laitinen J; Järvelin MR; Pouta A
    Am J Obstet Gynecol; 2008 Nov; 199(5):529.e1-529.e10. PubMed ID: 18533124
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Depo Provera. Position paper on clinical use, effectiveness and side effects.
    Bigrigg A; Evans M; Gbolade B; Newton J; Pollard L; Szarewski A; Thomas C; Walling M
    Br J Fam Plann; 1999 Jul; 25(2):69-76. PubMed ID: 10454658
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anaphylaxis from medroxyprogesterone acetate.
    Selo-Ojeme DO; Tillisi A; Welch CC
    Obstet Gynecol; 2004 May; 103(5 Pt 2):1045-6. PubMed ID: 15121602
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nondaily hormonal contraception: establishing a fit between product characteristics and patient preferences.
    Levine JP
    J Fam Pract; 2004 Nov; 53(11):904-13. PubMed ID: 15527729
    [No Abstract]   [Full Text] [Related]  

  • 16. Urinary tract infection in the users of depot-medroxyprogesterone acetate.
    Berger RE
    J Urol; 2005 Sep; 174(3):941. PubMed ID: 16093999
    [No Abstract]   [Full Text] [Related]  

  • 17. Depot medroxyprogesterone acetate contraception and the risk of breast and gynecologic cancer.
    Kaunitz AM
    J Reprod Med; 1996 May; 41(5 Suppl):419-27. PubMed ID: 8725705
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Body composition and weight gain in new users of the three-monthly injectable contraceptive, depot-medroxyprogesterone acetate, after 12 months of follow-up.
    dos Santos Pde N; Modesto WO; Dal'Ava N; Bahamondes MV; Pavin EJ; Fernandes A
    Eur J Contracept Reprod Health Care; 2014 Dec; 19(6):432-8. PubMed ID: 25047227
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sexually transmitted infections among women randomised to depot medroxyprogesterone acetate, a copper intrauterine device or a levonorgestrel implant.
    Deese J; Philip N; Lind M; Ahmed K; Batting J; Beksinska M; Edward VA; Louw CE; Onono M; Palanee-Phillips T; Smit JA; Baeten JM; Donnell D; Mastro TD; Mugo NR; Nanda K; Rees H; Morrison C
    Sex Transm Infect; 2021 Jun; 97(4):249-255. PubMed ID: 33208512
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In women over 35 years of age who smoke, does mirena (levonorgestrel-releasing intrauterine system) reduce the risk of DVTs compared to oral contraceptives?
    Marshall M; Jordan K; Brand JL; Welborn TL
    J Okla State Med Assoc; 2013 Sep; 106(9):362-3. PubMed ID: 24354055
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.